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Sciences Division, University of Southampton School of Medicine, Southampton General Hospital, Southampton, UKBackground & Aims: The pro-inﬂammatory functions of NF-jB Introduction
must be tightly regulated to prevent inappropriate tissue damage
and remodelling caused by activated inﬂammatory and wound-
healing cells. The p50 subunit of NF-jB is emerging as an impor-
tant repressor of immune and inﬂammatory responses, but by
mechanisms that are poorly deﬁned. This study aims to delineate
p50 target genes in activated hepatic stellate cells and to outline
mechanisms utilised in their repression.
Methods: Hepatic stellate cells were isolated from nfkb1(p50)-
deﬁcient or Wt mice and gene expression compared using micro-
array. Target genes were veriﬁed by qRT-PCR and p50-mediated
HDAC-1 recruitment to the target genes demonstrated using
chromatin immunoprecipitation.
Results:We identify p50 as transcriptional repressor of multiple
pro-inﬂammatory genes including Ccl2, Cxcl10, Gm-csf, and Mmp-
13. These genes are over-expressed in nfkb1(p50)-deﬁcient mice
suffering from chronic hepatitis and in ﬁbrogenic/inﬂammatory
hepatic stellate cells isolated from nfkb1/ liver. We identify
Mmp-13 as a bona-ﬁde target gene for p50 and demonstrate that
p50 is required for recruitment of the transcriptional repressor his-
tone deacetylase (HDAC)-1 to jB sites in the Mmp-13 promoter.
Chromatin immunoprecipitations identiﬁed binding of HDAC-1 to
speciﬁc regulatory regionsof theCcl2,Cxcl10,Gm-csfgenes that con-
tain predicted jB binding motifs. Recruitment of HDAC-1 to these
genes was not observed in nfkb1/ cells suggesting a requirement
for p50 in a manner similar to that described forMmp-13.
Conclusions: Recruitment of HDAC-1 to inﬂammatory genes pro-
vides a widespread mechanism to explain the immunosuppres-
sive properties of p50.
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kinase kinase kinase; IjB, inhibitor of kappa B.A limited but effective inﬂammatory response is essential for
ensuring neutralisation of microbial pathogens following infec-
tion and for the removal of damaged and necrotic cells resulting
from tissue trauma. However, this response is not without risk. If
inﬂammation fails to resolve (as in chronic disease) then the tis-
sue can be subject to signiﬁcant cellular damage caused by highly
toxic soluble factors (e.g. proteolytic enzymes) released by
inﬂammatory cells (neutrophils, eosinophils and macrophages)
that persist at the site of infection/trauma. For a ‘‘healthy” inﬂam-
matory response it is therefore important that the process fol-
lows its natural course from the initiation phase through to the
resolution phase [16,33]. Where this course is perturbed, and
inﬂammation fails to resolve, then there is potential for tissue
damage and pathological states [1,35]. Tight regulation of the
expression of inﬂammatory genes such as cytokines, chemokines,
cell adhesion molecules, and proteolytic enzymes is a key factor
in ensuring the appropriate induction and subsequent resolution
of inﬂammation [16,33].
NF-jB is now ﬁrmly established as a cardinal transcriptional
regulator of inﬂammatory gene expression and it is now emerg-
ing that different forms of NF-jB have distinct functions to play
in the inﬂammatory response [13]. Mammalian NF-jB functions
as homodimers or heterodimers generated from combinations of
ﬁve Rel family proteins (RelA, c-Rel, RelB, p50 and p52). The ﬁve
Rel family members share many conserved structural and func-
tional features, for example they all have a similar Rel homology
domain that enables dimerisation and DNA binding [12]. How-
ever, there are also distinctive structural and functional proper-
ties for each subunit which inﬂuence the activities of a
particular NF-jB dimer. RelA and p50 are constituents of the
so-called canonical NF-jB pathway that is thought to play a dom-
inant role in the control of inﬂammation [28]. The canonical
pathway is activated in response to a wide variety of inﬂamma-
tory stimuli including cytokines (e.g. TNF-a and IL-1b) and
ligands for the Toll-like receptors (e.g. lipopolysaccharide).
RelA:p50 NF-jB dimers are target end-points for the signaling
pathways triggered by these stimuli. Under resting conditions
these dimers are associated with the inhibitory protein IjBa.
IjBa lowers the efﬁciency of NF-jB transport to the nucleus
and interferes with DNA binding [30]. Inﬂammatory signals cul-
minate in the release of NF-jB from IjBa enabling interaction10 vol. 53 j 519–527
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with target jB sequence motifs in the regulatory regions of genes
controlling the inﬂammatory response. In general terms,
RelA:p50 functions to increase the rate of transcription of inﬂam-
matory genes. One way in which resolution of inﬂammation is
assured is that RelA:p50 stimulates transcription of IjBa to pro-
vide a rapid negative feedback mechanism. However, several
additional regulatory checkpoints operate to ensure tight control
of NF-jB-directed inﬂammation, including mechanisms provided
by the unique properties of the p50 subunit [41,43].
The p50 subunit lacks a transactivation domain and as a con-
sequence it can only stimulate transcription when either part-
nered with one of the transactivation domain-containing
subunits RelA, c-Rel or RelB (p52 also lacks a transactivation
domain), or when complexed with a transcriptional co-regulator
such as Bcl3 or CBP. Homodimers of p50 can act as transcriptional
repressors of pro-inﬂammatory genes and in this context are fea-
tures of endotoxin-tolerant and tumour-associated macrophages
[7,29,31,43]. Mice lacking the gene (nfkb1) encoding the p50 sub-
unit have highly elevated inﬂammatory responses to insults of
the lung, liver, and kidney suggesting that perhaps the predomi-
nant role of p50 is to operate as a negative regulator of NF-jB-
directed inﬂammation [14,24,26].
We have previously reported that nfkb1/ mice suffer
severe chronic inﬂammation and ﬁbrosis in a model of iterative
toxic injury of the liver [24]. An important cellular regulator of
the hepatic inﬂammatory and ﬁbrogenic response is the hepatic
stellate cell. This is a non-parenchymal liver cell that in
response to injury transdifferentiates into a wound-healing
myoﬁbroblasts [8,9]. In addition, recent data has shown that
hepatic stellate cells act as antigen presenting cells within the
liver [37,39]. These properties suggest a role for hepatic stellate
cells as important regulators of hepatic inﬂammation. In our
previous study we noted a perturbation of inﬂammatory signal-
ing in nfkb1/ hepatic stellate cells [24]. For example, these
cells aberrantly expressed TNF-a (both in vivo and in vitro)
which could be attenuated by reconstitution of p50. We there-
fore concluded that nfkb1/ hepatic stellate cells are a useful
model system to identify inﬂammatory genes that are subject
to transcriptional repression by p50, and subsequently to deter-
mine how p50 inhibits transcription. In the present study, we
identify 107 genes that are over-expressed in nfkb1/ hepatic
stellate cells and by studying p50 regulation of 4 of these genes
(Mmp-13, Gm-csf, Ccl2, and Cxcl10) we demonstrate that recruit-
ment of the histone deacetylase (HDAC)-1 transcriptional
repressor is a common mechanism by which p50 functions as
a negative regulator of inﬂammation.Materials and methods
Animal studies have been reviewed and approved by the Local Ethical Committee
and UK Home Ofﬁce.
Cell isolation and culture
Mouse hepatic stellate cells were isolated from C57Bl6 wild type or nfkb1/ liv-
ers as previously described [24] by incubation of liver segments with collagenase
and pronase, followed by discontinuous density centrifugation in 12% Optiprep
(Invitrogen). Hepatic stellate cells were cultured on plastic in Dulbecco’s modiﬁed
Eagle’s medium, supplemented with 100 U/ml penicillin, 100 lg/ml streptomy-
cin, 2 mM L-glutamine, and 16% fetal calf serum. Cell cultures were maintained
at 37 C at an atmosphere of 5% CO2.520 Journal of Hepatology 201Microarray analysis
To perform the microarray experiment, hepatic stellate cells were isolated from
groups of 3 animals from both C57Bl6 wild type and nfkb1/ mice as previously
described [24]. The cells were activated on plastic and passaged. Cells were har-
vested between passages 4 and 7 for microarray analysis. Four independent prep-
arations of wild type and nfkb1/ cells were used for the experiment. RNA was
extracted using Qiagen RNAeasy Kit (Qiagen UK) according to the manufacturer’s
instructions. RNA was only used if the A260/A280 ratio was between 1.8 and 2.1.
Each RNA prep was used to prepare a probe that was hybridised to a single array.
cRNA was synthesized from total RNA using the CodeLinkTM Expression Assay
Reagent Kit (GE Healthcare, Amersham, UK) according to the manufacturer’s
instructions. Probes were prepared by in vitro transcription, labelling, and frag-
mentation of the DNA and were hybridised to GE Healthcare CodeLinkTM Uniset
10K murine gene BioArrays (GE Healthcare, Amersham, UK) containing 10,458
probe sets. The arrays were washed according to the manufacturer’s instructions
and results visualised with a GenePixTM 4100A microarray scanner (Molecular
Devices, Wokingham, UK). Means of duplicates were used to analyse fold differ-
ences between wild type and nfkb1/ expression patterns and only genes with a
greater than 2-fold difference and a p <0.05 (by Student’s t-test) were considered
further. Ontological analysis of the genes differentially regulated between the two
genotypes was performed using Genespring software.
Chronic CCl4 liver injury model
Fibrogenesiswas induced by 12-week CCl4 treatment of 6 week old nfkb1/ or age
matchedWT littermates [24].Micewere injected IP twiceweeklywithCCl4/olive oil
in a 1:3 [vol/vol] ratio at 1 ll/g body weight. Twenty-four hours after the ﬁnal CCl4
administration, animals were sacriﬁced and liver samples prepared.
RNA extraction, cDNA synthesis and quantitative reverse transcriptase-polymerase
chain reaction (RT-PCR)
Total RNA was puriﬁed from isolated cells using the RNeasy puriﬁcation kit (Qia-
gen, UK) following the manufacturer’s instructions and was used to generate
cDNA utilising a random hexamer primer [p(dN)6] and MMLV reverse transcrip-
tase (Promega, UK). Primers for mouse Cxcl10, Mmp-13, Ccl2, Mmp3, and ﬁbro-
modulin were all purchased as Assays on demand (Applied Biosystems). All
PCRs were normalized to the internal control (18S) and relative level of transcrip-
tional difference calculated using the following equation: [1/(2A)]  100.
Crosslinked chromatin immunoprecipitation (XChIP) assay
Unless otherwise speciﬁed, ChIP assay was carried out using 20 lg crosslinked
chromatin prepared from activated hepatic stellate cells [18]. Antibodies used
for immunoprecipitation were raised against p50 (AbCam UK), p65 (Santa Cruz),
and HDAC-1 (Upstate UK). Ten micrograms of each antibody or appropriate irrel-
evant antibody control was used in each chip reaction. chip primers used in the
study were as follows – human MMP-13 promoter 50-aca ttg agt ttt ggg tta
ttg-30 (sense) and 50-ctt gat gac ttg gag gtg cta-30 (anti-sense); mouse Mmp-13
promoter 50-gcc aga gaa aaa tga ttg agc-30 (sense) and 50-ccc tgg gga taa ggt cat
ct-30 (anti-sense); rat MMP-13 promoter 50-ccc agt gaa gtg aaa aat-30 (sense)
and 50-gca gtg cct gga gtc tct-30 (anti-sense); mouse Gm-csf promoter jB4 site
50-ctg ggg aga cag caa aga ag-30 (sense) and 50-gca ctt gag acc ctg aga gg-30
(anti-sense); mouse Gm-csf promoter jB3 site 50-cga ttc atc aga gct cac ca-30
(sense) and 50-ctg ggt ggc ttg tat gtc ct-30 (anti-sense); mouse Gm-csf promoter
jB2 site 50-ttt gtc tct ggg tgg aaa cc-30 (sense) and 50-aaa ggc tcc att gca tca tc-
30 (anti-sense); mouse Gm-csf promoter jB1 site 50-tcg aaa gcc ctc act tct gt-30
(sense) and 50-cat gtc aag gtg gag gag gt-30 (anti-sense); mouse Ccl2 promoter
jB3 site 50-ggc tgg gga ttg atg ttc ta-30 (sense) and 50-tgg aaa ttc cca ttc tga gg-
30 (anti-sense); mouse Ccl2 jB2 site 50-atg tga gag cgc cac tct tt-30 (sense) and
50-tgg tag ctc tct gcc ctg tt-30 (anti-sense); mouse Ccl2 jB1 site 50-caa ggc ctg
ata acc aag ga-30 (sense) and 50-ggg gaa aga ggg aag aat tg-30 (anti-sense); mouse
Cxcl10 promoter jB3 site 50-acc ata ggg agc gga ctc tt-30 (sense) and 50-ttg aaa gca
gcc ctt tga ct-30 (anti-sense); Cxcl10 promoter jB2 site 50-tca aag ggc tgc ttt caa gt-
30 (sense) and 50-tcc aga ctt gcc tgt gtc tg-30 (anti-sense); mouse Cxcl10 jB1 site
50-tcc aag ttc atg ggt cac aa-30 (sense) and 50-gat gtc tct cag cgg tgg at-30 (anti-
sense). Each PCR was performed in triplicate and the analysis was repeated three
times from independent ChIP experiments. Real-time PCR analysis was per-
formed on an ABI 7500HT sequence detection system. In brief, qPCRs comprised
of 20 ng of cDNA template, 15 pmol each of sense and anti-sense oligonucleotide
primers, and 6.5 ll of Jumpstart SYBR green master mix (Sigma) in a total reaction0 vol. 53 j 519–527
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volume of 13 ll. After the initial 20 s incubation at 94 C, qPCRs were performed
using a 20 s annealing at 55 C followed by a 30 s elongation step at 72 C and a
5 s denaturation step at 94 C. After each run, a dissociation curve was performed
to ensure that no primer dimers contaminated the quantiﬁcation and that the
product had the expected melting temperature. A signal intensity value for each
sample was calculated from the average of the experiments. Average values of
eluates were normalized to average values of inputs after subtracting the back-
ground control, and differences between samples calculated using the following
equation: [1/(2A)]  100. Detailed ChIP protocol is available on request.
EMSA
NF-jB DNA binding was determined by EMSA as previously described [25] using
a 32P end-labeled double-stranded oligonucleotide probe (Promega) containing a
consensus NF-jB site. Nuclear extracts were prepared from p50 wt or EM1 and
EM2 mutant transfected LX2 cells using a previously published protocol [25].
Harvested cells were washed twice in ice-cold phosphate-buffered saline prior
to lysis in Buffer A supplemented with 0.2% Nonidet P-40, 0.5 mm 4-(2-amino-
ethyl)benzenesulfonyl ﬂuoride, 0.2 mm EDTA, and 15 lg/ml aprotinin. Lysates
were centrifuged for 10 s at 13,000 rpm to collect crude nuclear pellets. Superna-
tants were discarded and pellets were washed twice in lysis buffer without NP-40
prior to resuspension in Buffer C supplemented with 0.5 mm 4-(2-aminoethyl)
benzenesulfonyl ﬂuoride, 0.2 mm EDTA, and 15 lg/ml aprotinin. All buffers con-
tained protease inhibitor cocktail (Sigma, UK). After a 10-min incubation on ice
with occasional vortexing, the extracts were cleared of insoluble nuclear material
by centrifugation at 13,000 rpm for 30 s. Cleared nuclear extracts were trans-
ferred to fresh Eppendorf tubes, and their protein content was determined using
the Bradford DC assay kit (Bio-Rad). EMSA reactions were assembled on ice and
consisted of an initial 10-min incubation of 4 ll of Buffer C containing 2–10 lg
of nuclear protein extract and 12 ll of water containing 2 lg of poly(dI–dC). Four
microlitres of water containing 0.4 ng of radiolabeled double-stranded probe was
then added to the reaction and, after mixing, was incubated for a further 20 min.
EMSA reaction mixtures were then resolved by electrophoresis on an 8% non-
denaturing polyacrylamide gel (37:5:1).
Transfections and reporter gene assays
LX2 and 3T3 cells were transfected by the non-liposomal Effectene protocol (Qia-
gen) according to the manufacturer’s instructions. Luciferase assays were per-
formed using a dual luciferase kit (Promega) according to the manufacturer’s
instructions. MMP-13 promoter-driven expression of ﬁreﬂy luciferase was nor-
malized to protein concentration of the samples.
Constructs
MMP-13 promoter-luciferase reporter constructs were a kind gift from Dr. Ernes-
to Canalis (St. Francis Hospital and Research Centre, Connecticut, USA). Studies
described in this paper used a 721 bp fragment of MMP-13 promoter whichUp-regulated genes 
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Fig. 1. Genespring analysis of the ontologies of genes that are up or down-regulated
Journal of Hepatology 201encompasses 721 to +1 of rat MMP-13 promoter inclusive of NF-jB site at
498. The second MMP-13 promoter-luciferase reporter contains 227 bp frag-
ment of MMP-13 promoter encompassing 227 to +1 of rat MMP-13 promoter.
Generation of p50 mutants EM1 and EM2
p50 mutant constructs that are unable to homodimerise, namely EM1 and EM2,
were generated using two-step recombinant PCR as described previously [19].
EM1 carries Y267A/L269A mutations, whereas EM2 has further two residues
mutated so to make Y267A/L269A/F307A/V310A. Flag-tagged p50 wt expression
construct was used as template with following mutation introducing primers –
EM1 sense 50-ga ggg gag gaa att gct ctt gct tgt gac aaa gtt c-30 (mutated base pairs
underlined in all primers) and EM1 anti-sense 50-t ctg aac ttt gtc aca agc aag agc
aat ttc ct-30 . Once generated, EM1 construct was used as template to generate
EM2, utilising following mutation introducing primers – EM2 sense 50-cat aga
caa gcc gcc att gcc ttc aaa act cca-30 and EM2 anti-sense 50-tgg agt ttt gaa ggc
aat ggc ggc ttg tct atg-30 . Both mutants were cloned into pcDNA3 using HindIII/
XbaI restriction sites.Results
Loss of nfkb1/ results in widespread changes of genes controlling
inﬂammation and ﬁbrosis
Microarray and subsequent Genespring analysis revealed a total
of 228 genes that are differentially regulated by 2-fold or greater
betweenWt and nfkb1/ hepatic stellate cells (Fig. 1 and Supple-
mentary Tables 1 and 2). Of these genes, 107 were up-regulated
and 121 were down-regulated and represented genes involved in
a wide variety of physiological processes relevant to immunity
and wound-healing (Fig 1). As nfkb1/ mice display increased
susceptibility to carbon tetrachloride (CCl4)-induced inﬂamma-
tion and ﬁbrosis [24], we were particularly interested in genes
over-expressed in nfkb1/ hepatic stellate cells that regulate
these processes. Over-expressed inﬂammatory/ﬁbrogenic genes
identiﬁed include MMP-13 (38-fold); IL-1b (35-fold); Arginase 2
(13-fold), which is required for synthesis of proline, a critical
component of collagen; coagulation factor V (7-fold); IL-13
receptor a2 (7-fold), which mediates induction of TGF-b1 expres-
sion in response to IL-13; CXCL10 (7-fold); GM-CSF (6-fold); IL-11
(5-fold), a well known proﬁbrogenic cytokine; the acute phase
protein Ceruloplasmin (5-fold); Vanin 3 (4-fold), a pantetheinaseDown-regulated genes 
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Research Articleimplicated in inﬂammation; IL-15 (3-fold); and CCL2 (2.5-fold).
To validate the microarray data we employed qRT-PCR to
compare expression of MMP-13, CXCL10, GM-CSF, and CCL2
(up-regulated), ﬁbromodulin (down-regulated), and MMP-3 (no
difference) between Wt and nfkb1/ hepatic stellate cells. As
shown in Fig. 2, qRT-PCR conﬁrmed elevated expression of
MMP-13, CXCL10, GM-CSF and CCL2, and reduced expression of
ﬁbromodulin in nfkb1/ hepatic stellate cells with again no dif-
ference observed for MMP-3. Differences in the fold-increases
detected by microarray and qRT-PCR most likely reﬂect a variety
of technical differentials between the two methodologies as well
as differences in normalisation of microarray versus qRT-PCR
data. We also conﬁrmed that total hepatic expression of MMP-
13, CXCL10, and CCL2 are elevated for chronic CCl4-injured
nfkb1/ mice compared with Wt controls (Fig 3).0
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Results are expressed as relative transcriptional difference as compared to the
control ±SEM; n = 5.MMP-13 gene transcription is suppressed by the p50 product of
nfkb1
Since MMP-13 was highly over-expressed in nfkb1/ hepatic
stellate cells we were next interested to determine if the p50
product of nfkb1/ exerts any inﬂuence on MMP-13 expression
and gene transcription. We initially showed that over-expression
of p50 will suppress expression of endogenous MMP-13 (Fig. 4).
To investigate MMP-13 transcription, the human hepatic stellate
cell line LX2 [40] was transfected with MMP-13-promoter-lucif-
erase reporter constructs (Fig. 5A) together with an expression
vector for p50. Expression of p50 led to a 50% suppression of tran-
scription from a luciferase reporter containing a 721 nucleotide
long MMP-13 promoter. This effect was not observed with a
shorter 227 nucleotide promoter containing only the proximal
regulatory elements of the MMP-13 gene which by in silico anal-
ysis lacks a consensus jB site (Fig. 5B). Treatment with LPS or
TNF-a failed to relieve p50-mediated suppression of transcription
indicating the potential for p50 to inhibit MMP-13 expression
even under highly pro-inﬂammatory conditions (Fig. 5C).
HDAC-mediated repression of MMP-13 gene transcription
NF-jB dimers regulate transcription by binding to jB sequences
in the regulatory regions of target genes and via recruitment of522 Journal of Hepatology 201co-activators (e.g. p300/CBP) or co-repressors (e.g. HDAC-1)
which help to determine whether transcription is stimulated or
suppressed, respectively [2,6,10,34,42]. The p50 subunit of NF-
jB can form either pro-inﬂammatory heterodimers with RelA
or anti-inﬂammatory p50:p50 homodimers. The latter are
believed to actively suppress gene transcription through the
recruitment of histone deacetylases including HDAC-1 [6,42].0 vol. 53 j 519–527
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JOURNAL OF HEPATOLOGYChIP analysis showed that both p50 and RelA are recruited to the
MMP-13 promoter in hepatic stellate cells (Fig. 6A). Interaction of
p50 with the MMP-13 promoter was conﬁrmed with transfected
p50 (Fig. 6B). This binding was, as expected, dependent on p50
dimerisation since mutant p50 proteins (EM1 and EM2), contain-
ing mutations that disrupt amino-acid residues in the Rel homol-
ogy domain critical for p50 dimerisation, were not detected at the
MMP-13 promoter by ChIP (Fig. 6B and C). EM1 expresses a
mutant p50 that has amino acids Y270 and L272 mutated to ala-
nine; these two amino-acid residues are predicted to inﬂuence
homodimerisation and consequently DNA binding [32]. EM2 car-
ries the same two mutations plus an additional two amino acid
switches, F310 and V313 which are predicted to further perturb
DNA binding of p50 [32]. These predictions were proved correct
by EMSA analysis which showed reduced binding of EM1 to a
consensus jB site compared with wild type p50 and undetectable
binding of EM2 (Fig. 6D). We also detected binding of endoge-
nous (Fig. 6E) and transfected HDAC-1 (Fig. 6F) to the MMP-13
promoter. Furthermore, recruitment of HDAC-1 to the MMP-13
promoter was dependent on p50 since we did not detect binding
with ChIP in nfkb1/ cells (Fig. 6G). These data implicate HDAC-1
as a mediator of the suppressive effects of nfkb1/p50 on MMP-13
expression. To conﬁrm this idea we determined the effects of a
transfected HDAC-1 expression vector on MMP-13 promoter
activity in LX2. As shown in Fig. 7A, transfection of p50 alone
reduced MMP-13 transcription by 50% while co-transfection of
p50 and HDAC-1 resulted in 70% suppression of transcription.
By contrast treatment of hepatic stellate cells with the HDAC
inhibitor trichostatin A prevented the repressive effects of trans-
fected p50 and actually stimulated MMP-13 promoter activity
above the control levels (Fig. 7B). Trichostatin A treatment also
stimulated endogenous MMP-13 gene expression, with a 2-fold
induction at 4 h treatment rising to 5-fold after 8 h. Taken
together these data provide evidence that MMP-13 is a direct tar-
get for p50 which together with its co-repressor HDAC-1 acts to
suppress MMP-13 transcription. As p50 is absent in nfkb1/ cellsJournal of Hepatology 201and nfkb1/ mouse liver, but there was no difference in HDAC-1
expression [24], we suggest that loss of this mechanism provides
an explanation for the over-expression of MMP-13 in these cells
and tissues.
HDAC-1 recruitment is observed at multiple p50-repressed
promoters
We were next interested to determine if the elevated expres-
sion of GM-CSF, CCL2, and CXCL10 in nfkb1/ cells and liver0 vol. 53 j 519–527 523
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Research Articlewas associated with p50-dependent recruitment of HDAC-1 to
the regulatory regions of these genes. In silico analysis revealed
multiple jB sites in the upstream promoter regions of the
three genes (Fig. 8A). This information was used to select ChIP
primers spanning two different jB per gene promoter. ChIP
analysis of HDAC-1 recruitment to these regulatory sites was
then determined in wild type and nfkb1/ cells (Fig. 8B).
HDAC-1 binding was detected at one site in the GM-CSF gene
(3700), two sites in the CCl2 gene (420 and 700) and at
one site in the CXCL10 gene (100). All of these HDAC-1 inter-
actions were at near undetectable levels in nfkb1/ cells. The
p50:HDAC-1 complex is therefore a transcriptional suppressor
of multiple genes implicated in inﬂammation and tissue
remodelling.524 Journal of Hepatology 201Discussion
Inﬂammation is a highly regulated process that, if unchecked, can
lead to conditions of chronic tissue damage and accumulation of
ﬁbrotic tissue. NF-jB is a cardinal regulator of inﬂammation and
therefore continues to be extensively investigated with the hope
of development of improved anti-inﬂammatory drugs [5,15].
Homodimers of the p50 subunit of NF-jB are features of the
resolving phase of inﬂammatory responses and may operate as
important transcriptional inhibitors of NF-jB-regulated inﬂam-
matory genes [4]. The physiological consequences of loss of p50
expression have been documented in nfkb1-deﬁcient mice which
display enhanced M1-driven inﬂammation characterised by per-
turbed expression of TNF-a, IFN-b, CXCL10, and iNOS [29,31].0 vol. 53 j 519–527
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JOURNAL OF HEPATOLOGYThese mice are also susceptible to severe inﬂammatory responses
upon challenge of multiple organs [23,24,26]. Intratracheal infec-
tion of mice with Escherichia coli is associated with induction of
RelA/p50 dimers in the lung at 3 h which is followed by appear-
ance of p50/p50 dimers after 6 h, indicating a role for p50 homo-
dimers in resolution of lung inﬂammation [22]. Challenge of
nfkb1/ mice in this manner resulted in increased mortality, ele-
vated neutrophil recruitment to the lung, and over-expression of
KC, MIP-2, TNF-a, IL-6, and IL-1b at 6 h after infection [22]. In a
model of glomerular nephritis, Panzer et al. reported a similar
shift from RelA/p50 to p50/p50 dimers during transition from
the initiation to resolution phase of kidney inﬂammation [26].
Mice lacking nfkb1 displayed higher and prolonged expression
of CCL2, CCL5, and TNF-a, increased numbers of inﬁltrating
CD3+ cells and higher rates of mortality. We have previously
reported more severe inﬂammation and ﬁbrosis in nfkb1-deﬁ-
cient mice in a model of chronic liver ﬁbrosis [24]. Taken together
these models suggest that absence of p50 leads to the inappropri-
ate expression of a variety of pro-inﬂammatory mediators result-
ing in severe unresolved inﬂammation. The present study
improves our understanding of the role of p50 as a suppressor
of inﬂammation by revealing that its recruitment of HDAC-1 pro-
vides a mechanism for the negative transcriptional regulation of
at least four important pro-inﬂammatory genes (MMP-13, GM-
CSF, CCL2, and CXCL10) that are over-expressed in the injured
liver of nfkb1/ mice.cDNA microarray analysis revealed MMP-
13 as the gene up-regulated by the greatest extent (37.7-fold)
in nfkb1/ cells. MMP-13 is a protease with high selectivity for
insoluble ﬁbrillar collagens (in particular type I collagen) that is
expressed in response to a variety of inﬂammatory mediators
and in an NF-jB-dependent way [3,17,20,21]. The over-expres-
sion of MMP-13, in the context of the elevated ﬁbrosis observed
in chronic injured livers of nfkb1/ mice, may therefore seem
somewhat paradoxical. However, Uchinami et al. have previously
described the attenuation of liver ﬁbrosis in MMP-13 knockout
mice [36]. This effect results from MMP-13 being required for
the initial inﬂammatory response to injury which is a major
determinant of the subsequent ﬁbrogenic response. MMP-13Journal of Hepatology 201probably stimulates inﬂammation by promoting the release of
soluble active forms of inﬂammatory mediators (e.g. TNF-a) from
their insoluble ECM-bound states [36]. Of note, Uchinami
observed a dramatic reduction in neutrophil inﬁltration in the
sinusoids of injured MMP-13-deﬁcient mice [36]. A feature of
injured nfkb1/ liver is extremely high numbers of inﬁltrating
neutrophils [24]. Suppression of MMP-13 expression by p50/
p50 may therefore be an important mechanism for limiting neu-
trophilic inﬂammation and tissue damage. As demonstrated here,
transfection of p50 inhibits expression of endogenous MMP-13
and suppresses activity of an MMP-13 promoter-luciferase repor-
ter. Furthermore, both endogenous and transfected p50 can be
detected at the MMP-13 promoter by ChIP. Speciﬁcity of this
binding was conﬁrmed by showing that dimerisation- and
DNA-binding-defective p50 proteins fail to ChIP to the promoter.
Our data, however, does not exclude the possibility that NF-jB
subunits other than p50 and RelA may bind selected target genes.
MMP-13 is therefore a bona-ﬁde target gene for p50 which under
conditions of excess relative to RelA will promote repression of
MMP-13 gene transcription. Such conditions are described in
the resolving phase of inﬂammation where p50/p50 dominates
over RelA/p50 dimers [11]. We conclude that absence of p50 is
responsible for the highly elevated expression of MMP-13 (as
well as CXCL10 and CCL2) in nfkb1/ cells and liver. This also
supports the hypothesis that absence of p50 is responsible for
the severe inﬂammatory responses of nfkb1/ mice. Of note,
cells lacking the nfkb1 gene effectively lack two proteins (p105
and p50) and also display defects in the expression and activity
of the MAP3K Tpl2/Cot [27]. Hence, attributing phenotypes
observed in nfkb1/ cells and mice to functions of p50 requires
substantiation with additional experiments such as those we
describe above.
As p50 lacks a transactivation domain its inﬂuences on tran-
scription are dependent either upon dimerisation with RelA, c-
Rel or RelB, or on the activities of co-regulators that assemble
functional complexes with p50 at gene promoters. Co-regulators
implicated as adapters of p50 function include HDAC-1, the IjB
family protein Bcl3, and the histone acetylase CBP [10,34,42].0 vol. 53 j 519–527 525
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Fig. 8. HDAC-1 binds to GM-CSF, CCL2, and CXCL10 NF-jB sites in vivo. (A)
Schematic representation of putative NF-jB site within regulatory regions of GM-
CSF, CCL2, and CXCL10 genes. (B) Crosslinked chromatin was prepared fromWt or
nfkb/ HSCs. Twenty micrograms of chromatin was incubated with 10 lg of anti-
HDAC-1 antibody or non-speciﬁc control; ChIP assay was carried out and regions
surrounding putative NF-jB sites within GM-CSF promoter (B), CCL2 promoter
(C), and CXCL10 promoter (D) were ampliﬁed. Several sites were found to bind
HDAC-1 which are shown in the ﬁgure. Error bars represent ±SEM; n = 3.
Research ArticleThe nature and type of p50:co-regulator complex assembled,
appear to be context dependent and may result in stimulation
or repression of transcription. For example, p50:p50:HDAC-1
assembles at the TNF-a promoter to inhibit transcription, by
contrast p50:p50:CBP assembles at the IL-10 promoter in macro-
phages responding to LPS and stimulates transcription [4]. The
p50:p50:HDAC-1 prevents inappropriate transcription of TNF-a
in ﬁbrogenic hepatic stellate cells [24]. We were therefore
interested to determine if a similar mechanism operates at the
MMP-13 gene. Both endogenous and transfected HDAC-1 were
associated with the MMP-13 promoter in wild type but not in
nfkb1/ cells. HDAC-1 over-expression enhanced the repressive526 Journal of Hepatology 201effects of p50 on the MMP-13 promoter, while treatment of cells
with the HDAC inhibitor trichostatin A blocked the repressive
effects of transfected p50 on MMP-13. Recruitment of a p50
and HDAC-1 containing complex at the TNF-a and MMP-13 genes
raises the possibility that this complex operates as an orchestra-
tor of the inhibition of multiple pro-inﬂammatory genes. We
showed that HDAC-1 associated with jB site-containing
upstream regions of genes encoding GM-CSF, CCL2, and CXCL10,
all of which are expressed at higher levels in nfkb1/ cells and
liver tissue compared with wild type. The interaction of
HDAC-1 with these genes was detected in wild type but not in
nfkb1/ cells conﬁrming a requirement of p50 for recruitment
of HDAC-1.
Previous work has identiﬁed the TNF-a, IL-6, and iNOS genes
as being repressed by HDAC-1 in a p50-dependent manner
[24,42]. A similar mechanism operates at the HIV-1 long terminal
repeat to promote latency of the virus, with potential for pro-
inﬂammatory signals to relieve this mechanism and stimulate
viral replication [38]. By us now showing that p50-dependent
recruitment of HDAC-1 orchestrates repression of MMP-13,
GM-CSF, CCL2, and CXCL10 in a model of chronic liver inﬂamma-
tion and ﬁbrosis, it can be concluded that the p50:p50:HDAC-1
complex is a master negative regulator of inﬂammation. The chal-
lenge is to deﬁne the molecular control of the recruitment and
assembly of p50:p50:HDAC-1 and how this control is modulated
in chronic unresolved states of inﬂammation.Conﬂict of Interest
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